Scientists have cracked the code behind how bacteria naturally produce multiple versions of powerful anti-cancer drugs. By identifying tiny molecular connectors called "docking domains," researchers at the University of Warwick can now reverse-engineer nature's process to design new, more targeted cancer therapies — including improved versions of existing FDA-approved treatments like Romidepsin.
For decades, scientists knew bacteria could churn out multiple versions of potent anti-cancer compounds — they just couldn't figure out how. Now, researchers at the University of Warwick have finally cracked the code, publishing their findings in Nature Communications. The key? Tiny molecular connectors called docking domains that act like puzzle pieces, linking different enzyme systems together so bacteria can mix and match components to produce a variety of related drug molecules with remarkable precision.
The discovery centers on a family of cancer drugs called HDAC inhibitors, which regulate gene expression inside cells. This includes Romidepsin (Istodax), an FDA-approved treatment for T-cell lymphomas. The team also identified the previously unknown biological pathway bacteria use to produce a related compound, FR-901375 — a gap that had stumped researchers for years. Armed with this blueprint, scientists can now engineer synthetic drug-making pathways to generate entirely new anti-cancer candidates with better potency, improved selectivity, and fewer side effects.
Key Takeaways:
Why it matters: This breakthrough moves cancer drug discovery from observation to engineering — giving researchers a nature-tested toolkit to design better therapies faster.
